Glomerular Disease in Temporal Association with SARS-CoV-2 Vaccination: A Series of 29 Cases

Tiffany N. Caza, Clarissa A. Cassol, Nidia Messias, Andrew Hannoudi, Randy S. Haun, Patrick D. Walker, Rebecca M. May, Regan M. Seipp, Elizabeth J. Betchick, Hassan Amin, Mandolin S. Ziadie, Michael Haderlie, Joy Eduwu-Okwuwa, Irina Vancea, Melvin Seek, Essam B. Elashi, Ganesh Shenoy, Sayeed Khalillullah, Jesse A. Flaxenburg, John BrandtMatthew J. Diamond, Adam Frome, Eugene H. Kim, Gregory Schlessinger, Erlandas Ulozas, Janice L. Weatherspoon, Ethan Thomas Hoerschgen, Steven L. Fabian, Sung Yong Bae, Bilal Iqbal, Kanwalijit K. Chouhan, Zeina Karam, James T. Henry, Christopher P. Larsen

Research output: Contribution to journalArticlepeer-review

51 Scopus citations

Abstract

Background Immune responses to vaccination are a known trigger for a new onset of glomerular disease or disease flare in susceptible individuals. Mass immunization against SARS-CoV-2 in the COVID-19 pandemic provides a unique opportunity to study vaccination-associated autoimmune kidney diseases. In the recent literature, there are several patient reports demonstrating a temporal association of SARS-CoV-2 immunization and kidney diseases. Methods Here, we present a series of 29 cases of biopsy-proven glomerular disease in patients recently vaccinated against SARS-CoV-2 and identified patients who developed a new onset of IgA nephropathy, minimal change disease, membranous nephropathy, ANCA-associated GN, collapsing glomerulopathy, or diffuse lupus nephritis diagnosed on kidney biopsies postimmunization, as well as recurrent ANCA-associated GN. This included 28 cases of de novo GN within native kidney biopsies and one disease flare in an allograft. Results The patients with collapsing glomerulopathy were of Black descent and had two APOL1 genomic risk alleles. A brief literature review of patient reports and small series is also provided to include all reported cases to date (n=52). The incidence of induction of glomerular disease in response to SARS-CoV-2 immunization is unknown; however, there was no overall increase in incidence of glomerular disease when compared with the 2 years prior to the COVID-19 pandemic diagnosed on kidney biopsies in our practice. Conclusions Glomerular disease to vaccination is rare, although it should be monitored as a potential adverse event.

Original languageEnglish
Pages (from-to)1770-1780
Number of pages11
JournalKidney360
Volume2
Issue number11
DOIs
StatePublished - Nov 1 2021

Keywords

  • ANCA
  • APOL1
  • COVID-19
  • IgA nephropathy
  • SARS-CoV-2 vaccine
  • collapsing glomerulopathy
  • crescentic glomerulonephritis
  • glomerular and tubulointerstitial diseases
  • lupus nephritis
  • membranous nephropathy
  • minimal change disease

Fingerprint

Dive into the research topics of 'Glomerular Disease in Temporal Association with SARS-CoV-2 Vaccination: A Series of 29 Cases'. Together they form a unique fingerprint.

Cite this